Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University.
Investors erased $40 bln of market value after Reuters revealed the U.S. company knew for decades its baby power was sometimes tainted by asbestos. Based on past consumer scandals, the real hit could be smaller but long-lasting. Lawsuits and brand damage don’t easily dissipate.
It might buy a stake in $33 bln U.S. insurer Aflac, which does business mostly in Japan. Financial conglomerates that mix banking and insurance have a patchy record; so does Japan Post when it comes to overseas acquisitions. At least this would be a watered-down version of both.
Today’s bird weighs up to five times as much as 60 years ago, putting it on track to be the world’s protein of choice. Yet the rate of growth is slowing because of the fowl’s physical limits. That’s a recipe for lab-grown alternatives, just as regulators clarify the rules.